Malignancy-associated haemophagocytic lymphohistiocytosis in adults

The Lancet Oncology

Volumn 18, Issue 2, 2017, Pages 169-171

  Daver, Naval ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD8 ANTIGEN; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MEPREDNISONE; NI 0501; RUXOLITINIB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT DISEASE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HEMATOLOGIC MALIGNANCY; HEMOPHAGOCYTIC SYNDROME; HUMAN; MACROPHAGE; MALIGNANT NEOPLASM; MOLECULAR MECHANICS; NATURAL KILLER CELL; NOTE; PRACTICE GUIDELINE; ADULT; NEOPLASM;

ADULT; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; NEOPLASMS;

EID: 85011932097     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30004-9     Document Type: Note

References (10)

1. 1 Haroche, JCF, Rollins, B, Donadieu, J, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol 18 (2017), e113–e125.
2. 2 Machaczka, M, Vaktnas, J, Klimkowska, M, Hagglund, H, Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma 52 (2011), 613–619.
3. 3 Tamamyan, GN, Kantarjian, HM, Ning, J, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes. Cancer 122 (2016), 2857–2866.
4. 4 Parikh, SA, Kapoor, P, Letendre, L, Kumar, S, Wolanskyj, AP, Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 89 (2014), 484–492.
5. 5 Otrock, ZK, Eby, CS, Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 90 (2015), 220–224.
6. 6 Lee, DW, Gardner, R, Porter, DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195.
7. 7 Henter, JI, Arico, M, Egeler, RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 28 (1997), 342–347.
8. 8 Henter, JI, Horne, A, Arico, M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 (2007), 124–131.
9. 9 Lehmberg, K, Nichols, KE, Henter, JI, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica 100 (2015), 997–1004.
10. 10 Jordan, M, Locatelli, F, Allen, C, A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH. Blood, 126, 2015 LBA-3 (abstr).